Lupin launches asthma, COPD drug Luforbec in UK
Luforbec is first branded generic alternative to Fostair 100/6 g pMDI for treatment of Asthma and COPD.
Mumbai: Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited, today announced that following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, it has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal).
Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US.
In the twelve months to May 2021, the NHS spent over £177 million on Fostair 100/6 pMDI.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
Next Story
